Maximum Approved Dose of Zepbound (Tirzepatide)
The maximum approved dose of Zepbound (tirzepatide) is 15 mg administered subcutaneously once weekly 1, 2.
Dosing Information
The FDA-approved dosing for Zepbound includes three maintenance dose options:
- 5 mg once weekly
- 10 mg once weekly
- 15 mg once weekly (maximum dose)
All doses are administered as a subcutaneous injection once per week 1, 2.
Clinical Context
In the pivotal SURMOUNT-1 trial, the 15 mg weekly dose demonstrated the greatest efficacy, with mean weight loss of 20.9% at 72 weeks in adults with obesity 3. The guideline evidence from the 2025 ADA Standards of Care confirms 15 mg as the maximum approved daily (weekly) dose for tirzepatide 1.
Real-world data shows that while 15 mg is the maximum approved dose, only 25.9% of patients actually reach this maximum dose in clinical practice, with most patients achieving meaningful weight loss at lower doses 4. The medication is typically started at a lower dose and titrated upward based on tolerability and response.
Important Considerations
- The 15 mg dose is used for both diabetes (Mounjaro) and obesity (Zepbound) indications 5
- Dose escalation occurs over a 20-week period to minimize gastrointestinal side effects 3
- The most common adverse events are gastrointestinal and typically mild-to-moderate, occurring primarily during dose escalation 3
- Treatment discontinuation due to adverse events occurred in 6.2% of participants receiving the 15 mg dose in clinical trials 3
The 15 mg maximum dose provides the greatest weight reduction and cardiometabolic benefits, though lower maintenance doses (5 mg or 10 mg) may be appropriate based on individual tolerability and treatment goals 2, 3.